Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Go back to Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy| Gilead Sciences (NASDAQ: GILD) | Delayed: 130.17 -0.17 (0.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.34 | 52 Week High | $108.63 | |||
| Open | $129.22 | 52 Week Low | $71.39 | |||
| Day High | $130.54 | P/E | 71.92 | |||
| Day Low | $127.61 | EPS | $1.81 | |||
| Volume | 2,558,916 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 130.11 +2.64 (2.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $127.47 | 52 Week High | $65.46 | |||
| Open | $127.82 | 52 Week Low | $47.97 | |||
| Day High | $131.04 | P/E | 88.51 | |||
| Day Low | $127.82 | EPS | $1.47 | |||
| Volume | 4,462,564 | |||||
